Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Other Gross PP&E Adjustments (2016 - 2025)

Iovance Biotherapeutics has reported Other Gross PP&E Adjustments over the past 10 years, most recently at $92.7 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $92.7 million for Q4 2025, up 89.23% from a year ago — trailing twelve months through Dec 2025 was $92.7 million (up 89.23% YoY), and the annual figure for FY2025 was $92.7 million, up 89.23%.
  • Other Gross PP&E Adjustments for Q4 2025 was $92.7 million at Iovance Biotherapeutics, down from $117.4 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for IOVA hit a ceiling of $143.6 million in Q3 2024 and a floor of $49.0 million in Q4 2024.
  • Median Other Gross PP&E Adjustments over the past 3 years was $75.5 million (2023), compared with a mean of $84.4 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 125.95% in 2024 and later dropped 23.21% in 2025.
  • Iovance Biotherapeutics' Other Gross PP&E Adjustments stood at $50.8 million in 2023, then dropped by 3.6% to $49.0 million in 2024, then surged by 89.23% to $92.7 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $92.7 million (Q4 2025), $117.4 million (Q3 2025), and $102.9 million (Q2 2025) per Business Quant data.